Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome

Genes & Immunity volume 15, pages 54–56 (2014)Cite this article

Subjects

Abstract

Sjogren’s syndrome (SS) is a chronic autoimmune disorder with the highest risk for lymphoma development among all autoimmune diseases. In order to evaluate whether the presence of the recently described MYD88 L265P mutation in patients with Waldenström's macroglobulinemia (WM) is contributory to SS-associated lymphomagenesis, a quantitative allele-specific PCR method was performed in peripheral blood derived from 90 SS patients as well as in minor salivary gland tissues derived from 12 primary SS patients with or without lymphoma. MYD88 L265P was not detected in either of the samples tested. Although the absence of the MyD88 L265P somatic mutation in our SS cohort does not exclude a common germline susceptibility gene in SS, it might suggest a distinct operating pathogenetic mechanism in SS-related lymphoma compared with WM and other hematological malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Zintzaras E, Voulgarelis M, Moutsopoulos HM . The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337–2344.

    Article  Google Scholar 

  2. Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM . Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 2012; 91: 1–9.

    Article  Google Scholar 

  3. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011; 70: 1363–1368.

    Article  Google Scholar 

  4. Manoussakis MN, Boiu S, Korkolopoulou P, Kapsogeorgou EK, Kavantzas N, Ziakas P et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007; 56: 3977–3988.

    Article  CAS  Google Scholar 

  5. Voulgarelis M, Skopouli FN . Clinical immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol 2007; 32: 265–274.

    Article  CAS  Google Scholar 

  6. Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2012; 52: 276–281.

    Article  Google Scholar 

  7. Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun (e-pub ahead of print 9 July 2013; doi:10.1016/j.jaut.2013.04.005).

    Article  CAS  Google Scholar 

  8. Sisto M, Lisi S, Lofrumento DD, Ingravallo G, De Lucro R, D'Amore M . Salivary gland expression level of IkappaBalpha regulatory protein in Sjogren's syndrome. J Mol Histol 2013; 44: 447–454.

    Article  CAS  Google Scholar 

  9. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012; 367: 826–833.

    Article  CAS  Google Scholar 

  10. Kristinsson SY, Koshiol J, Bjorkholm M, Goldin LR, McMaster ML, Turesson I et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Nat Cancer Inst 2010; 102: 557–567.

    Article  CAS  Google Scholar 

  11. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.

    Article  CAS  Google Scholar 

  12. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121: 2051–2058.

    Article  CAS  Google Scholar 

  13. Mavragani CP, Crow MK . Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010; 35: 225–231.

    Article  CAS  Google Scholar 

  14. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A . Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603–607.

    Article  CAS  Google Scholar 

  15. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A . Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev 2012; 12: 282–294.

    CAS  Google Scholar 

  16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554–558.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Aristea Papageorgiou, MD for helping in the recruitment of SS patients, Adrianos Nezos, PhD and Efstathia Kapsogeorgou, PhD for performing DNA extractions of peripheral blood and minor salivary gland tissues, respectively, and S Niarchos Foundation for financial support.

Author information

Author notes

  1. M Voulgarelis and C P Mavragani: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece

    M Voulgarelis & H M Moutsopoulos

  2. Department of Physiology, School of Medicine, University of Athens, Athens, Greece

    C P Mavragani

  3. Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    L Xu & S P Treon

Authors
  1. M Voulgarelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C P Mavragani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S P Treon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H M Moutsopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Voulgarelis.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voulgarelis, M., Mavragani, C., Xu, L. et al. Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome. Genes Immun 15, 54–56 (2014). https://doi.org/10.1038/gene.2013.54

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gene.2013.54

Keywords

Search

Advanced search

Quick links